<PAGE>
----------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934.
For the quarterly period ended March 31, 1997
Commission File Number 0-20945
MEDI-JECT CORPORATION
161 Cheshire Lane, Suite 100
Minneapolis, Minnesota 55441
(612) 475-7700
A Minnesota Corporation IRS Employer ID No. 41-1350192
----------------
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
The number of shares outstanding of the Registrant's Common Stock, $.01 par
value, as of April 30, 1997 was 6,994,664.
----------------
<PAGE>
MEDI-JECT CORPORATION
INDEX
<TABLE>
<CAPTION>
PAGE
----
PART I. FINANCIAL INFORMATION
<S> <C> <C>
ITEM 1. Financial Statements (Unaudited)
Balance Sheets, as of December 31, 1996 and
March 31, 1997....................................... 3
Statements of Operations for the three months ended
March 31, 1996 and 1997.............................. 4
Statements of Cash Flows for the three months ended
March 31, 1996 and 1997.............................. 5
Notes to Financial Statements........................ 6
ITEM 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.................. 7
PART II. OTHER INFORMATION
ITEM 6. Exhibits and Reports on Form 8-K..................... 8
SIGNATURES..................................................... 11
</TABLE>
2
<PAGE>
MEDI-JECT CORPORATION
BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
December 31, March 31,
1996 1997
------------ ------------
ASSETS
<S> <C> <C>
Current Assets:
Cash and cash equivalents.................. $ 9,575,240 $ 6,303,217
Marketable securities...................... 1,464,277 3,963,906
Accounts receivable, less allowances
for doubtful accounts of $12,983........... 537,755 856,653
Inventories................................ 351,330 386,167
Prepaid expenses and other assets.......... 86,589 203,643
------------ ------------
12,015,191 11,713,586
------------ ------------
Equipment, furniture and fixtures, net.......... 595,590 616,552
------------ ------------
Patent rights................................... 345,010 366,093
------------ ------------
$ 12,955,791 $ 12,696,231
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
(DEFICIT)
Current liabilities:
Accounts payable........................... $ 353,456 504,137
Accrued expenses and other liabilities..... 331,446 480,179
Deferred revenue........................... 14,019 39,019
Capital lease obligations - current
maturities................................. 32,747 24,797
Notes payable - current maturities......... 96,097 64,858
------------ ------------
827,765 1,112,990
------------ ------------
Long-term liabilities:
Capital lease obligations, less
current maturities......................... 8,350 5,267
Notes payable, less current maturities..... -- --
------------ ------------
8,350 5,267
------------ ------------
Shareholders' equity (deficit):
Common Stock: $0.01 par; authorized
17,000,000 shares:
6,925,636 and 6,959,627 issued and
outstanding at December 31, 1996 and
March 31, 1997, respectively.............. 69,256 69,596
Additional paid-in capital................. 23,590,887 23,631,135
Accumulated deficit........................ (11,540,467) (12,122,757)
------------ ------------
Total shareholders' equity............... 12,119,676 11,577,974
------------ ------------
$ 12,955,791 $ 12,696,231
============ ============
</TABLE>
See accompanying notes to financial statements.
3
<PAGE>
MEDI-JECT CORPORATION
STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Year Ended
----------------------
March 31, March 31,
1996 1997
---------- ----------
<S> <C> <C>
Revenues:
Sales............................................. $ 443,825 $ 406,081
Licensing & product development................... 325,323 564,944
---------- ----------
769,148 971,025
---------- ----------
Operating Expenses:
Cost of sales..................................... 292,511 270,048
Research and development.......................... 449,732 645,290
General and administrative........................ 389,334 407,830
Sales and marketing............................... 212,654 366,362
---------- ----------
1,344,231 1,689,530
---------- ----------
Net operating loss................................. (575,083) (718,505)
---------- ----------
Other income (expense):
Interest and other income......................... 35,548 139,995
Interest and other expense........................ (13,481) (3,780)
---------- ----------
22,067 136,215
---------- ----------
Net loss........................................... $ (553,016) $ (582,290)
========== ==========
Net loss per common share.......................... -- $ (.08)
Weighted average common shares
outstanding....................................... -- 6,947,245
Proforma net loss per common share
(unaudited) (Note 3).............................. $ (.14)
Proforma weighted average common shares
outstanding (unaudited) (Note 3).................. 4,087,360
</TABLE>
See accompanying Notes to Financial Statements
4
<PAGE>
MEDI-JECT CORPORATION
STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Quarter Ended
------------------------
March 31, March 31,
1996 1997
---------- -----------
<S> <C> <C>
Cash flows from operating activities:
Net loss......................................... $ (553,016) $ (582,290)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation..................................... 32,304 56,356
Interest on marketable debt securities........... -- (35,676)
Shares issued as compensation.................... -- --
Amendments to investor option agreement.......... -- --
Changes in operating assets and liabilities:
Accounts receivable............................ (149,289) (318,898)
Inventories.................................... (16,028) (34,837)
Prepaid expenses and other assets.............. (43,805) (117,054)
Accounts payable............................... 119,611 150,681
Accrued liabilities............................ (77,627) 148,733
Deferred revenue............................... 60,678 25,000
---------- -----------
Net cash used in operating activities................ (627,172) (707,985)
---------- -----------
Cash flows from investing activities:
Purchases of marketable securities............... -- (2,463,953)
Purchases of equipment, furniture and fixtures... (78,868) (67,021)
Purchase of patent rights........................ (60,308) (31,380)
---------- -----------
Net cash used in investing activities................ (139,176) (2,562,354)
---------- -----------
Cash flows from financing activities:
Principal payments on capital lease obligations.. (11,994) (11,033)
Proceeds from issuance of common stock........... -- 46,279
Proceeds from issuance of convertible preferred
stock........................................... 3,812,500 --
Warrants issued.................................. 125,000 --
Proceeds from issuance of notes payable.......... 187,500 --
Principal payments on notes payable.............. (339,936) (31,239)
Offering costs................................... (231,770) (5,691)
---------- -----------
Net cash provided by (used in) financing activities.. 3,541,300 (1,684)
---------- -----------
Net increase (decrease) in cash and cash equivalents. 2,774,952 (3,272,023)
Cash and cash equivalents:
Beginning of period.............................. 35,817 9,575,240
---------- -----------
End of period.................................... $2,810,769 $ 6,303,217
========== ===========
</TABLE>
See accompanying Notes to Financial Statements.
5
<PAGE>
MEDI-JECT CORPORATION
NOTES TO FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10
of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by generally accepted accounting principles for
complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary
for a fair presentation have been included. The accompanying financial
statements and notes should be read in conjunction with the Company's 1996
audited financial statements and notes thereto.
2. INTERIM FINANCIAL STATEMENTS
Operating results for the three month period ended March 31, 1997 are not
necessarily indicative of the results that may be expected for the year
ending December 31, 1997.
3. PRO FORMA NET LOSS PER SHARE
Pro forma net loss per share is computed by dividing the net loss
attributable to common shareholders by the weighted average number of
shares of common stock and common stock equivalents outstanding, after
applying the treasury stock method and after giving effect to the reverse
stock split and the automatic conversion of all outstanding shares of
convertible preferred stock in accordance with the Company's initial public
offering.
Pursuant to certain requirements of the Securities and Exchange Commission,
common stock equivalents include the impact of the issuance of stock,
options and warrants within one year prior to the date of the initial
filing of the Company's initial public offering ("IPO") at exercise prices
less than the initial public offering price per share, whether or not the
effects are antidilutive.
4. Inventories consist of the following:
<TABLE>
<CAPTION>
December 31, 1996 March 31, 1997
----------------- --------------
<S> <C> <C>
Raw Material $175,251 $208,799
Work in-process 119,575 107,738
Finished goods 56,504 69,630
-------- --------
$351,330 $386,167
======== ========
</TABLE>
6
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Results of Operations
Three Months Ended March 31, 1996 and 1997
Total revenues for the three months ended March 31, 1996 and 1997 were $769,148
and $971,025 respectively. This represents an increase of $201,877 or 26%. Sales
of injector products and services decreased by $37,744 in the three months ended
March 31, 1997, compared to the three months ended March 31, 1996. This decrease
resulted primarily from a decrease in the number of injectors sold (811 and 629
in the first quarters of 1996 and 1997, respectively) partially offset by
increased sales of supplies and services. The decrease in sales of injectors in
the quarterly periods is primarily attributable to the shipment of a significant
order to a corporate customer in the first quarter of 1996 that did not occur in
the 1997 period.
Licensing and product development fee income increased by $239,621 in the three
months ended March 31, 1997 as compared to the prior year period. This increase
relates to development and licensing fees received from agreements with
corporate partners that were not in existence in the first quarter of 1996. The
Company expects that licensing and product development fee income will fluctuate
on a quarter to quarter basis, depending on a number of factors, including the
timing of the execution of new development and licensing agreements and the
timing, nature and size of fee payments to be made under existing and new
agreements. In addition, since the Company does not, in general, recognize
project-based fee income until related development work has been performed,
quarterly results will fluctuate with the timing of the Company's research and
development efforts.
Cost of sales in the three months ended March 31, 1996 and 1997 were $292,511
and $270,048, respectively. This represents a decrease of $22,463. The decrease
in cost of sales is primarily attributable to decreased sales in the first
quarter of 1997.
Research and development expenses totaled $449,732 and $645,290 in the three
months ended March 31, 1996 and 1997, respectively. This increase is primarily
attributable to expenditures related to development projects underway in the
first quarter of 1997 for corporate partners that were not in existence in the
first quarter of 1996.
General and administrative expenses totaled $389,334 and $407,830 in the three
months ended March 31, 1996 and 1997, respectively. These figures reflect an
increase of $18,496 or 5%. This increase is primarily attributable to increased
auditing and amoritzation expense in 1997. The amortization expense relates to
the initiation of patent amortization charges following the allowance by the
U.S. Patent Office of one of the Company's patent filings in February, 1997.
Sales and marketing expenses totaled $212,652 and $366,362 in the three months
ended March 31, 1996 and 1997, respectively. These figures reflect a year to
year increase of $153,710 or 72%. This increase is primarily attributable to
personnel additions, increased travel expense and expenditures related to the
launch of the new Medi-Jector Choice product in January 1997.
7
<PAGE>
Interest expense totaled $13,481 and $3,780 in the three month periods ended
March 31, 1996 and 1997, respectively. The decrease is attributable to lower
overall indebtedness in 1997. Interest income increased relative to the prior
year for these same periods as a result of increased cash on hand following the
Company's inital public offering in October, 1996.
Liquidity and Capital Resources
Cash, cash equivalents and marketable securities totaled $11,039,517 on December
31, 1996 compared to $10,267,123 on March 31, 1997. This decrease results
primarily from an operating loss of $582,290 and an increase in accounts
receivable and prepaid expenses totaling $435,952, during the period, which were
partially offset by an increase in current liabilities of $285,225.
The Company's long term capital requirements will depend on numerous factors,
including the status of the Company's collaborative arrangements, the progress
of the Company's research and development programs and the receipt of revenues
from the sales of the Company's products. The Company believes that cash on
hand, interest expected to be earned thereon and anticipated revenues, will meet
its needs through 1997. In order to meet its capital needs beyond this period,
the Company may be required to raise additional capital through public or
private offerings, including equity offerings.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 2. Changes in Securities
None
Item 3. Defaults Upon Senior Securities.
None
Item 4. Submission of Matters to a Vote of Securities Holders.
None
Item 5. Other Information.
None
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
3.1 Second Amended and Restated Articles of Incorporation of the
Company.(a)
8
<PAGE>
3.2 Second Amended and Restated Bylaws of the Company.(a)
4.1 Form of Certificate for Common Stock.(a)
4.2 Stock Warrant, dated January 25, 1996, issued to Becton
Dickinson and Company.(a)
4.3 Stock Option, dated January 25, 1996, issued to Becton
Dickinson and Company.(a)
4.4 Warrant, dated March 24, 1995, issued to Robert Fullerton.(a)
4.5 Warrant, dated March 24, 1995, issued to Michael Trautner.(a)
4.6 Preferred Stock, Option and Warrant Purchase Agreement, dated
January 25, 1996, between the Company and Becton Dickinson and
Company (filed herewith as Exhibit 10.7).(a)
10.1 Office/Warehouse/Showroom Lease, dated January 2, 1995,
including amendments thereto.(a)
10.3 Security Agreement, dated September 30, 1994, by and between
the Company and Kelsey Lake Limited Partnership and Kerry Lake
Company, a Limited Partnership.(a)
10.4 Promissory Note, dated September 30, 1994, issued to Kelsey
Lake Limited Partnership.(a)
10.5 Promissory Note, dated September 30, 1994, issued to Kerry
Lake Company, a Limited Partnership.(a)
10.6 Loan Agreement, dated as of December 22, 1995, by and between
Ethical Holdings plc and the Company, including the related
Promissory Note, dated December 22, 1995, issued to Ethical
Holdings plc.(a)
10.7 Preferred Stock, Option and Warrant Purchase Agreement, dated
January 25, 1996, between the Company and Becton Dickinson and
Company.(a)
10.8 * Employment Agreement, dated as of January 1, 1997, between the
Company and Franklin Pass, MD.
10.9 * Employment Agreement, dated as of January 3, 1995, between the
Company and Mark Derus.(a)
10.10 * Employment Agreement, dated as of January 3, 1995, between
the Company and Todd Leonard.(a)
9
<PAGE>
10.11 * Employment Agreement, dated as of January 3, 1995, between
the Company and Peter Sadowski.(a)
10.12 * 1993 Stock Option Plan.(a)
10.13 * Form of incentive stock option agreement for use with 1993
Stock Option Plan.(a)
10.14 * Form of nonqualified stock option agreement for use with 1993
Stock Option Plan.(a)
10.15 * 1996 Stock Option Plan, with form of stock option
agreement.(a)
+10.20 Development and License Agreement between Becton Dickinson
and Company and the Company, effective January 1, 1996.(a)
10.21 Office-Warehouse lease with Carlson Real Estate Company,
dated February 11, 1997.
27 Financial Data Schedule
* Indicates management contract or compensatory plan or arrangement.
(a) Incorporated by reference to the Company's Registration Statement on Form
S-1 (File No. 333-6661), filed with the Securities and Exchange Commission
on October 1, 1996.
+ Pursuant to Rule 406 of the Securities Act of 1933, as amended,
confidential portions of Exhibit 10.20 were deleted and filed separately
with the Securities and Exchange Commission pursuant to a request for
confidential treatment, which was subsequently granted by the Securities and
Exchange Commission.
10
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MEDI-JECT CORPORATION
May 14, 1997 /s/ Franklin Pass
- ----------------------------------- ------------------------------------------
Date Franklin Pass, MD, Chairman/CEO
May 14, 1997 /s/ Mark S. Derus
- ----------------------------------- ------------------------------------------
Date Mark S. Derus, Vice President Finance, CFO
Principal Financial & Accounting Officer
11
<PAGE>
EMPLOYMENT AGREEMENT
--------------------
THIS AGREEMENT, dated as of January 1, 1997, by and between Medi-Ject
Corporation, a Minnesota corporation (the "Company"), and Franklin Pass, M.D. an
individual resident of Hennepin County in the State of Minnesota ("Executive").
WHEREAS, the Company wishes to employ Executive to render services for the
Company on the terms and conditions set forth in this Agreement, and Executive
wishes to be retained and employed by the Company on such terms and conditions.
NOW, THEREFORE, in consideration of the premises and the respective
undertakings of the Company and Executive set forth below, the Company and
Executive agree as follows:
1. Employment. The Company hereby employs Executive, and Executive
accepts such employment and agrees to perform services for the Company, for the
period and upon the other terms and conditions set forth in this Agreement.
2. Term. Unless terminated at an earlier date in accordance with
Section 9 of this Agreement, the term of Executive's employment hereunder shall
be for a period commencing on the date of this Agreement and continuing until
December 31, 2000 (the "Initial Term"), and, thereafter, the term of this
Agreement shall be automatically extended for successive one (1) year periods
(each an "Extension Term"), unless either party gives written notice to the
other party of its intention to terminate this Agreement which notice shall be
given not less than ninety (90) days prior to the end of the Initial Term or any
Extension term.
3. Position and Duties.
--------------------
3.01 Service with Company. During the term of this Agreement, Executive
agrees to perform such reasonable employment duties as the Board of Directors of
the Company shall assign to him from time to time consistent with the position
of Chairman, President and Chief Executive Officer of the Company, to which he
has been elected.
3.02 Performance of Duties. Executive agrees to serve the Company
faithfully and to the best of his ability, to devote his full time, attention
and efforts to the management of business and affairs of the Company during the
term of this Agreement. Executive hereby confirms that he is under no
contractual commitments inconsistent with his obligations set forth in this
Agreement, and that during the term of this Agreement, he will not render or
perform services for any other corporation, firm, entity or person that are
inconsistent with the provisions of this Agreement except that he may serve as a
director of nonprofit charitable corporations and may serve as a director of or
a consultant to other for profit corporations so long as such service does not
materially detract from his full time commitment to the Company and does not
violate Sections 5 and 7 hereof.
1
<PAGE>
4. Compensation.
-------------
4.01. Base Salary. As compensation in full for services to be rendered by
the Executive under this Agreement during the first year of the Initial Term the
Company shall pay to Executive a base annual salary of $210,000, which salary
shall be paid in accordance with the Company's normal payroll procedures and
policies. The compensation payable to Executive during each subsequent year
during the term of this Agreement shall be mutually agreed upon by the Company
and Executive prior to the commencement of each such year but shall not be less
than $210,000 multiplied by a fraction, the denominator of which is the consumer
price index (CPI) in effect on January 1, 1997, and the numerator of which is
the CPI in effect on the last day of each year of the Initial Term or any
Extension Term. As used herein, CPI refers to the Consumer Price Index, All
Items, U.S. Cities Average (base year 1982--1984) published by the Bureau of
Labor Statistics.
4.02. Participation in Benefit Plans. Executive shall also be entitled to
participate in all employee benefit plans or programs (including vacation time)
of the Company to the extent that his position, title, tenure, salary, age,
health and other qualifications make him eligible to participate. The Company
does not guarantee the adoption or continuance of any particular employee
benefit plan or program during the term of this Agreement, and Executive's
participation in any such plan or program shall be subject to the provisions,
rules and regulations applicable thereto. In addition to the normal employee
benefit programs of the company, Executive shall be eligible for reimbursement
or direct payment of expenses incurred for additional life insurance policies
representing an aggregate policy amount of $2,000,000 and additional disability
insurance premiums not to exceed $10,000 in each calendar year.
4.03 Expenses. The Company will pay or reimburse Executive for all
reasonable and necessary out-of-pocket expenses incurred by him in the
performance of his duties under this Agreement, subject to the presentment of
appropriate vouchers in accordance with the Company's normal policies for
expense verification.
4.04 Stock Options. By December 31, 1997, the Company will issue to
Executive options to purchase 400,000 shares of Common Stock of the Company,
$.01 par value, to expire no less than ten years from the date of issuance, on
the following terms and conditions:
(a) If possible, such options shall be issued pursuant to an amendment
to Medi-Ject Company's 1996 Incentive and Stock Option Plan, which
the Company will use its best efforts to have adopted by the Board
of Directors and the shareholders of the Company. If issued under
the Plan, the option price shall be the Fair Market Value of the
Common Stock of the Company as defined in the Plan as of the date of
issuance of the options, but in no event more than $5.50 per share.
The options granted shall be Incentive Stock Options to the extent
permissible under the terms of the Plan and the Internal Revenue
Code, and Non-Qualified Stock Options to the extent of the balance.
Executive shall vest in the options over the period from the date of
grant through December 31, 2000, pro rata on a monthly basis as of
the last day of each month, but with an initial vesting percentage
equal to 1/48 times
2
<PAGE>
the number of last days of the month that have elapsed between
January 1, 1997 and the date of grant of the option. Options shall
vest during any month only if Executive is in the employ of the
Company as of the last day of the month. Executive shall also become
100% vested on his death, Disability as defined in Section 8.03(a),
or Change in Control as defined below, in all instances, if he is in
the employ of the Company as of the date of the occasioning event.
(b) If such options cannot be issued pursuant to an amended Medi-Ject
Corporation 1996 Incentive and Stock Option Plan, then the Company
shall issue Executive non-qualified options, subject to shareholder
approval of such grant, and shall submit such grant to shareholders
for their approval at the next meeting of shareholders held after
the date of such grant. The option price shall be the fair market
value of the Common Stock of the Company as of the date of issuance
of the options, but in no event more than $5.50 per share. Executive
shall vest in the options over the period from the date of grant
through December 31, 2000, pro rata on a monthly basis as of the
last day of each month, but with an initial vesting percentage equal
to 1/48 times the number of last days of the month that have elapsed
between January 1, 1997 and the date of grant of the option. Options
shall vest during any month only if Executive is in the employ of
the Company as of the last day of the month. Executive shall also
become 100% vested on his death, Disability, as defined below, or
Change in Control, in all instances, if he is in the employ of the
Company as of the date of the occasioning event.
(c) In the event the shareholders of the Company do not approve either
the amendment ot the Company's 1996 Incentive and Stock Option Plan
or the grant outside of the 1996 Incentive and Stock Option Plan,
then Executive and the Company agree to negotiate in good faith an
altrenative to the stock options contemplated hereby which would
provide Executive and the Company with similar incentives and
rewards which would not require the approval of the Company's
shareholders.
(d) "Change of Control" shall mean any of the following events:
(i) The acquisition by any person or entity (including any group
of persons or entities that are acting in concert or otherwise
affiliated), directly or indirectly of the Beneficial
Ownership (as defined in Section 13(d) of the Securities
Exchange Act of 1934, as amended) of any voting security of
the Company if immediately after such acquisition such person
or entity is, directly or indirectly, the Beneficial Owner of
voting securities representing 50% or more of the total voting
power of all of the then-outstanding voting securities of the
Corporation;
(ii) The election as members of the Board of Directors of the
Company individuals who, as of the date of this Agreement, are
not members of the
3
<PAGE>
Board of Directors of the Company, unless the election of such
individuals is supported by the existing members of the Board;
(iii) A merger, consolidation, recapitalization, reorganization,
reverse stock split, or any similar transaction with respect
to the Company's securities, other than any such transaction
which would result in at least 75% of the total voting power
represented by the voting securities of the surviving entity
outstanding immediately after such transaction being
Beneficially Owned by the holders of the outstanding voting
securities of the Company immediately prior to the
transaction, with the voting power of each such continuing
holder relative to other such continuing holders not
substantially altered in the transaction; or
(iv) The complete liquidation of the Company or the sale or
disposition by the Company of assets constituting 50% or more
of value of the Company.
(e) The Company's obligation to issue options pursuant to this Section
4.04 shall survive the termination of this Agreement.
5. Confidential Information. Except as permitted or directed by the
Company's Board of Directors, during the term of this Agreement and for a period
of five years thereafter, Executive shall not divulge, furnish or make
accessible to anyone or use in any way (other than in the ordinary course of the
business of the Company) any confidential or secret knowledge or information of
the Company which Executive has acquired or become acquainted with or will
acquire or become acquainted with prior to the termination of the period of his
employment by the Company, whether developed by himself or by others, concerning
any trade secrets, confidential or secret designs, processes, formulae, plans,
devices or material (whether or not patented or patentable) directly or
indirectly useful in any aspect of the business of the Company, any customer or
supplier lists of the Company, any confidential or secret development or
research work of the Company, or any other confidential information or secret
aspects of the business of the Company. Executive acknowledges that the above-
described knowledge or information constitutes a unique and valuable asset of
the Company and represents a substantial investment of time and expense by the
Company and its predecessors, and that any disclosure or other use of such
knowledge or information other than for the sole benefit of the Company would be
wrongful and would cause irreparable harm to the Company. The foregoing
obligations of confidentiality, however, shall not apply to any knowledge or
information which is now published or which subsequently becomes generally
publicly known in the industry other than as a direct or indirect result of the
breach of this Agreement by Executive.
6. Noncompetition and Nonsolicitation Covenants.
---------------------------------------------
6.01 Agreement Not to Compete. Executive agrees that, during the term of
his employment by the Company and (a) for a period of one year thereafter should
his employment be terminated by the Company without cause or should he terminate
his employment for cause or (b) for a period of two years thereafter should his
employment be terminated by the Company for
4
<PAGE>
cause, or should he terminate his employment without cause, all as defined in
Section 8 hereof, he shall not, directly or indirectly, engage in competition
with the Company in any manner or capacity (e.g., as an advisor, principal,
agent, partner, officer, director, stockholder, employee, member of any
association, or otherwise) in any phase of the business that the Company is
conducting during the term of this Agreement, including the design, development,
manufacture, distribution, marketing or designing of accessories, devices, or
systems related to the products or services being sold by the Company.
6.02 Geographic Extent of Covenant. The obligations of Executive under
Section 6.01 shall apply to any geographic area in which the Company:
(a) has engaged in business during the term of this Agreement through
production, promotional, sales or marketing activity, or
(b) has otherwise established its goodwill, business reputation, or any
customer or supplier relations.
6.03 Limitation on Covenant. Ownership by Executive, as a passive
investment, of less than two percent (2%) of the outstanding shares of the
capital stock of any corporation listed on a national securities exchange or
publicly traded in the over-the-counter market shall not constitute a breach of
this Section 6.
6.04 Nonsolicitation and Noninterference. For a period of two years
following the term of this Agreement, Executive shall not directly or indirectly
(a) induce or attempt to induce any employee of the Company to leave the employ
of the Company, (b) induce or attempt to induce any employee of the Company to
work for, render services or provide advise to or supply confidential business
information or trade secrets of the Company to any third person, firm or
corporation or (c) induce or attempt to induce any customer, supplier, licensee,
licenser or other business relation of the Company to cease doing business with
the Company, or in any way interfere with the relationship between any such
customer, supplier, licensee, or licensor and the Company.
7. Patent and Related Matters.
---------------------------
7.01 Disclosure and Assignment. Executive will promptly disclose in
writing to the Company complete information concerning each and every invention,
discovery, improvement, device, design, apparatus, practice, process, method or
product, whether patentable or not, made, developed, perfected, devised,
conceived or first reduced to practice by Executive, either solely or in
collaboration with others, during the term of this Agreement, or within six
months thereafter, whether or not conceived during regular working hours,
relating either directly or indirectly to the business, products, practices, or
techniques of the Company (hereinafter referred to as "Developments").
Executive, to the extent that he has the legal right to do so, hereby
acknowledges that any and all of said Developments are the property of the
Company and hereby assigns and agrees to assign to the Company any and all of
Executive's right, title and interest in and to any and all of such
Developments. Without limiting the foregoing, any and all original
5
<PAGE>
works of authorship which are created by Executive (solely or jointly with
others) within the scope of Executive's employment and which are protectable by
copyright law shall be deemed "works made for hire," as that term is defined in
the U.S. Copyright Act (17 U.S.C. Section 101).
7.02 Future Developments. As to any future Developments made by Executive
that relate to the business, products or practices of the Company and that are
first conceived or reduced to practice during the term of this Agreement, or
within six months thereafter, but that are claimed for any reason to belong to
an entity or person other than the Company, Executive will promptly disclose the
same confidentially and in writing to the Company and shall not disclose the
same to others if the Company, within twenty (20) days thereafter, shall claim
ownership of such Developments under the terms of this Agreement. If the Company
makes such claim, Executive agrees that, insofar as the rights (if any) of
Executive are involved, it will be settled by arbitration in accordance with the
rules then obtaining of the American Arbitration Association. The locale of the
arbitration shall be Minneapolis, Minnesota or other locale convenient to the
Company's principal executive offices.
7.03 Limitation on Sections 7.01 and 7.02. The provisions of Sections
7.01 and 7.02 shall not apply to any Development meeting the following
conditions:
(a) such Development was developed entirely on Executive's own time;
(b) such Development was made without the use of any Company equipment,
supplies, facility or trade secret information.
(c) such Development does not relate (i) directly to the business of the
Company, or (ii) to the Company's actual or demonstrable anticipated
research.
(d) such Development does not result from any work performed by
Executive for the Company.
7.04 Assistance of Executive. Upon request and without further
compensation therefor, but at no expense to Executive, and whether during the
term of this Agreement or thereafter, Executive will do all lawful acts,
including, but not limited to, the execution of papers and lawful oaths and the
giving of testimony, that in the opinion of the Company, its successors and
assigns, may be necessary or desirable in obtaining, sustaining, reissuing,
extending and enforcing United States and foreign Letters Patent, including, but
not limited to, design patents, on any and all of such Developments, and for
perfecting, affirming and recording the Company's complete ownership and title
thereto, and to cooperate otherwise in all proceedings and matters relating
thereto.
7.05 Records. Executive will keep complete, accurate and authentic
accounts, notes, data and records of all Developments in the manner and form
reasonably requested by the Company. Such accounts, notes, data and records
shall be the property of the Company, and, upon its request, Executive will
promptly surrender the same to it or, if not previously
6
<PAGE>
surrendered upon its request or otherwise, Executive will surrender the same,
and all copies thereof, to the Company upon the conclusion of his employment.
7.06 Obligations, Restrictions and Limitations. Executive understands
that the Company may enter into Agreements or arrangements with agencies of the
United States Government, and that the Company may be subject to laws and
regulations which impose obligations, restrictions and limitations on it with
respect to inventions and patents that may be acquired by it or that may be
conceived or developed by employees, consultants or other agents rendering
services to it. Executive agrees that he shall be bound by all such obligations,
restrictions and limitations applicable to any such invention conceived or
developed by him during the term of this Agreement and shall take any and all
further action that may be required to discharge such obligations and to comply
with such restrictions and limitations.
8. Termination.
------------
8.01 Grounds for Termination. This Agreement shall terminate prior to the
expiration of the Initial Term or any Extension Term in the event that at any
time during the Initial Term or any Extension Term:
(a) Executive shall die;
(b) Executive shall become disabled as defined in Section 8.03 hereof;
(c) the Board of Directors of the Company shall determine that:
(i) Executive has breached this Agreement in one or more material
respects, other than a breach of Section 3.02 hereof, which
breach causes or may cause substantial monetary injury to the
Company or its business, and is not cured by Executive or is
not capable of being cured by Executive within thirty (30)
days after written notice of such breach is delivered to
Executive by the Board of Directors following a meeting at
which Executive has been heard on the issue in question.
(ii) Executive has engaged in willful misconduct which conduct is
materially injurious to the Company and its business,
(iii) Executive has breached Section 3.02 of this Agreement, and
such breach is not cured by Executive or is not capable of
being cured by Executive within thirty (30) days after written
notice of such breach is delivered to Executive by the Board
of Directors following a meeting at which Executive has been
heard on the issue in question.
Termination pursuant to this Section 8(c) (i), (ii), and (iii) shall
be deemed termination for cause;
7
<PAGE>
(d) Executive is terminated by the Company without cause following not
less than ninety days prior written notice of such termination.
(e) Executive terminates this Agreement because of a material breach
thereof by the Company including a reduction in his compensation or
duties.
Notwithstanding any termination of this Agreement, Executive, in
consideration of his employment hereunder to the date of such termination,
shall remain bound by the provisions of this Agreement that specifically
relate to periods, activities, or obligations upon or subsequent to the
termination of Executive's employment.
8.02 Severance. In the event Executive's employment is terminated by the
Company pursuant to Section 8.01(d) or is terminated by Executive pursuant to
Section 8.01(e), the Company shall pay Executive, as severance, the lesser of
two years Base Salary or Executive's Base Salary for the remainder of the
Initial Term or any Extension Term of this Agreement. Executive shall be paid
such severance in the same manner as Base Salary had theretofore been paid.
Executive shall have no obligation of mitigation and shall, in all events, be
entitled to severance without regard to subsequent employment. If Executive's
employment is terminated pursuant to Section 8.01(c) or if Executive terminates
his employment without cause, no severance will be paid to Executive by the
Company.
8.03 "Disability" Defined. The Board of Directors may determine that
Executive has become disabled, for the purpose of this Agreement, in the event
that Executive shall fail, because of illness or incapacity, to render services
of the character contemplated by this Agreement over a period of ninety (90)
days during any one hundred and eighty (180) day period. The existence or
nonexistence of grounds for termination because of disability shall be made in
good faith by the Board of Directors after notice in writing given to Executive
at least thirty (30) days prior to such determination. During such thirty (30)
day period, Executive shall be permitted to make a presentation to the Board of
Directors with respect to the disability determination.
8.04 Surrender of Records and Property. Upon termination of his
employment with the Company, Executive shall deliver promptly to the Company all
records, manuals, books, blank forms, documents, letters, memoranda, notes,
notebooks, reports, data, tables, calculations or copies thereof, which are the
property of the Company or which relate in any way to the business, products,
practices or techniques of the Company, and all other property, trade secrets
and confidential information of the Company, including, but not limited to, all
documents which in whole or in part contain any trade secrets or confidential
information of the Company, which in any of these cases are in his possession or
under his control.
8
<PAGE>
9. Miscellaneous.
--------------
9.01 Governing Law. This Agreement is made under and shall be governed by
and construed in accordance with the laws of the State of Minnesota.
9.02 Prior Agreements. This Agreement contains the entire Agreement of
the parties relating to the subject matter hereof and supersedes all prior
Agreements and understandings with respect to such subject matter, and the
parties hereto have made no Agreements, representations or warranties relating
to the subject matter of this Agreement which are not set forth herein.
9.03 Withholding Taxes. The Company may withhold from any benefits
payable under this Agreement all federal, state, city or other taxes as shall be
required pursuant to any law or governmental regulation or ruling.
9.04 Amendments. No amendment or modification of this Agreement shall be
deemed effective unless made in writing and signed by the parties hereto.
9.05 No Waiver. No term or condition of this Agreement shall be deemed to
have been waived, nor shall there be any estoppel to enforce any provisions of
this Agreement, except by a statement in writing signed by the party against
whom enforcement of the waiver or estoppel is sought. Any written waiver shall
not be deemed a continuing waiver unless specifically stated, shall incorporate
only as to the specific term or condition waived and shall not constitute a
waiver of such term or condition for the future or as to any act other than that
specifically waived.
9.06 Severability. To the extent any provision of this Agreement shall be
invalid or unenforceable, it shall be considered deleted herefrom and the
remainder of such provision and of this Agreement shall be unaffected and shall
continue in full force and effect. In furtherance and not in limitation of the
foregoing, should the duration or geographical extent of, or business activities
covered by, any provision of this Agreement be in excess of that which is valid
and enforceable under applicable law, then such provision shall be construed to
cover only that duration, extent or activities which may validly and enforceable
be covered. Executive acknowledges the uncertainty of the law in this respect
and expressly stipulates that this Agreement be given the construction which
renders its provisions valid and enforceable to the maximum extent (not
exceeding its express terms) possible under applicable law.
9.07 Assignment. This Agreement shall not be assignable, in whole or in
part, by either party without the written consent of the other party, except
that the Company may, without the consent of Executive, assign its rights and
obligations under this Agreement to any corporation, firm or other business
entity with or into which the Company may merge or consolidate, or to which the
Company may sell or transfer all or substantially all of its assets, or of which
50% or more of the equity investment and of the voting control is owned,
directly or indirectly, by, or is under common ownership with, the Company.
After any such assignment by the Company, the Company shall be discharged from
all further liability hereunder and such assignee shall thereafter
9
<PAGE>
be deemed to be the Company for the purposes of all provisions of this Agreement
including this Section 9.07.
9.08 Injunctive Relief. Executive agrees that it would be difficult to
compensate the Company fully for damages for any violation of the provisions of
this Agreement, including without limitation the provisions of Sections 5, 6, 7,
and 8.04. Accordingly, Executive specifically agrees that the Company shall be
entitled to temporary and permanent injunctive relief to enforce the provisions
of this Agreement and that such relief may be granted without the necessity of
proving actual damages. This provision with respect to injunctive relief shall
not, however, diminish the right of the Company to claim and recover damages in
addition to injunctive relief.
IN WITNESS WHEREOF, Executive and the Company have executed this Agreement
as of the date set forth in the first paragraph.
MEDI-JECT CORPORATION EMPLOYEE
By:_______________________________ _____________________________
Franklin Pass, M.D.
Its: ___________________________
10
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND> This schedule contains summary financial information extracted from
audited and unaudited internal financial statements and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<CIK> 0001016169
<NAME> Medi-Ject Corporation
<S> <C> <C>
<PERIOD-TYPE> 12-MOS 3-MOS
<FISCAL-YEAR-END> DEC-31-1996 DEC-31-1997
<PERIOD-START> JAN-01-1996 JAN-01-1997
<PERIOD-END> DEC-31-1996 MAR-31-1997
<CASH> 9575240 6303217
<SECURITIES> 1464277 3963906
<RECEIVABLES> 550738 869636
<ALLOWANCES> 12983 12983
<INVENTORY> 351330 386167
<CURRENT-ASSETS> 12015191 11713586
<PP&E> 1238584 1305604
<DEPRECIATION> 642994 689053
<TOTAL-ASSETS> 12955791 12696231
<CURRENT-LIABILITIES> 827765 1112990
<BONDS> 8350 5267
0 0
0 0
<COMMON> 69256 69596
<OTHER-SE> 12050420 11508378
<TOTAL-LIABILITY-AND-EQUITY> 12955791 12696231
<SALES> 1837704 406081
<TOTAL-REVENUES> 3930859 1111020<F1>
<CGS> 1136272 270048
<TOTAL-COSTS> 5001221 1419482
<OTHER-EXPENSES> 0 0
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> 31934 3780
<INCOME-PRETAX> (2238568) (582290)
<INCOME-TAX> 0 0
<INCOME-CONTINUING> (2238568) (582290)
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> (2238568) (582290)
<EPS-PRIMARY> (.39) (.08)
<EPS-DILUTED> (.39) (.08)
<FN>
<F1> Includes interest income of $230,655 for PE 12-31-96 and $139,919 for PE
3-31-97.
</FN>
</TABLE>
